O'Flaherty E - Search Results

1

Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors.

Rasko JE, O'Flaherty E, Begley CG. Rasko JE, et al. Stem Cells. 1997;15(1):33-42. doi: 10.1002/stem.150033. Stem Cells. 1997. PMID: 9007220

2

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG. Basser RL, et al. Blood. 2002 Apr 1;99(7):2599-602. doi: 10.1182/blood.v99.7.2599. Blood. 2002. PMID: 11895799 Free article.

3

Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF).

O'Flaherty E, Cook W, Boyd J, Grant SL, Kurek J, Begley CG. O'Flaherty E, et al. Growth Factors. 2002 Sep;20(3):141-5. doi: 10.1080/0897719021000032038. Growth Factors. 2002. PMID: 12519017

4

Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.

O'Flaherty E, Cebon J, Grigg AP. O'Flaherty E, et al. Leuk Lymphoma. 1997 Oct;27(3-4):343-9. doi: 10.3109/10428199709059689. Leuk Lymphoma. 1997. PMID: 9402332

5

Bone marrow stromal function from patients after bone marrow transplantation.

O'Flaherty E, Sparrow R, Szer J. O'Flaherty E, et al. Bone Marrow Transplant. 1995 Feb;15(2):207-12. Bone Marrow Transplant. 1995. PMID: 7539666

6

Perturbation in the ability of bone marrow stroma from patients with acute myeloid leukemia but not chronic myeloid leukemia to support normal early hematopoietic progenitor cells.

Sparrow RL, O'Flaherty E, Blanksby TM, Szer J, Van Der Weyden MB. Sparrow RL, et al. Leuk Res. 1997 Jan;21(1):29-36. doi: 10.1016/s0145-2126(96)00068-9. Leuk Res. 1997. PMID: 9029183

7

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic.

Purtill D, Antonenas V, Chiappini P, Tong D, O'Flaherty E, Bajel A, Kabani K, Larsen S, Tan S, Hutchins C, Curtis DJ, Kennedy GA, Watson AM, Bai L, Greenwood M, Gottlieb DJ, Hamad N. Purtill D, et al. Blood Adv. 2020 Sep 8;4(17):4147-4150. doi: 10.1182/bloodadvances.2020002431. Blood Adv. 2020. PMID: 32886750 Free PMC article.

8

Cyclosporin A for the treatment of pure red cell aplasia associated with myelodysplasia.

Grigg AP, O'Flaherty E. Grigg AP, et al. Leuk Lymphoma. 2001 Nov-Dec;42(6):1339-42. doi: 10.3109/10428190109097761. Leuk Lymphoma. 2001. PMID: 11911417

9

Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease.

Atkinson K, Farrelly H, Cooley M, O'Flaherty E, Downs K, Biggs J. Atkinson K, et al. Bone Marrow Transplant. 1987 Jun;2(1):51-7. Bone Marrow Transplant. 1987. PMID: 3332157

10

CD4+ T cells appear capable of initiating graft-versus-host disease across non-major histocompatibility complex (MHC) barriers in man.

Atkinson K, Cooley M, Farrelly H, O'Flaherty E, Ashby M, Biggs J. Atkinson K, et al. Bone Marrow Transplant. 1987 Jun;2(1):79-84. Bone Marrow Transplant. 1987. PMID: 2901876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters